✦ LIBER ✦

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

✍ Scribed by Gschaidmeier, H; Hoelzer, D; Ottmann, O G; Wassmann, B; Pfeifer, H; Scheuring, U; Klein, S A; Gökbuget, N; Binckebanck, A; Martin, H

Book ID: 110055326
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 141 KB
Volume: 16
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402770

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nilotinib and donor lymphocyte infusion

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

✍ Mario Tiribelli; Alessandra Sperotto; Anna Candoni; Erica Simeone; Silvia Buttig 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 223 KB

The extent of minimal residual disease r

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

✍ Seok Lee; Yoo-Jin Kim; Nak-Gyun Chung; Jihyang Lim; Dong-Gun Lee; Hee-Je Kim; Ch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 2 views

## Abstract ## BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐positive ALL). Here, the authors analyzed for risk factors that af